Your session is about to expire
← Back to Search
Other
Effect of Intravitreally Administered AIV007 in Subjects With nAMD
Phase 1
Waitlist Available
Research Sponsored by AiViva BioPharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 224 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a special gel injected into the eye for patients with a severe eye condition called neovascular age-related macular degeneration. The gel releases medicine slowly to help manage the disease.
Eligible Conditions
- Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ approximately 224 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 224 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events
Secondary study objectives
Mean change from baseline in BCVA
Mean change from baseline in central subfield thickness as measured by optical coherence tomography
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: AIV007 Treatment Dose 3Experimental Treatment1 Intervention
Intravitreal, Dose 3
Group II: AIV007 Treatment Dose 2Experimental Treatment1 Intervention
Intravitreal, Dose 2
Group III: AIV007 Treatment Dose 1Experimental Treatment1 Intervention
Intravitreal, Dose 1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AIV007
2020
Completed Phase 1
~10
Find a Location
Who is running the clinical trial?
AiViva BioPharma, Inc.Lead Sponsor
5 Previous Clinical Trials
97 Total Patients Enrolled
1 Trials studying Macular Degeneration
30 Patients Enrolled for Macular Degeneration